Abstract
In 2020, immunotherapy, alone or in combination with conventional chemotherapy, is the reference treatment for non-small cell lung cancer without oncogenic driver mutation consist. A new concept of oligometastatic disease emerged during those last years, suggesting that integrating a local ablative therapy with a systemic one could modify the course of the neoplastic disease. Pre-clinical data are showing a synergistic effect between immunotherapy (antiPD1/PDL1 or antiCTLA4) and radiotherapy, strong rationale for considering combination of both treatments in oligometastatic cancer. Into clinic, data, yet if clinically meaningful, remain preliminary. Numerous prospective trials, randomised or not, are underway and should answer this question in the next few years.© 2020 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
